 HOLON, Israel, July 19, 2021 PRNewswire -- Compugen Ltd. Nasdaq: CGEN, a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that the first patient has been dosed in the cohort expansion arm of the Phase 12 study evaluating the triple combination of COM701, Compugens first-in-class anti-PVRIG antibody, with Opdivo nivolumab and Bristol Myers Squibbs investigational anti-TIGIT antibody, BMS-986207. 